HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer

1. HER2DX assay is prognostic for event-free survival in early-stage breast cancer.

2. Study analyzed data from 11 studies with 2,518 patients.

3. 50% of patients had high HER2DX risk scores.

4. 93.6% event-free survival for low-risk group vs 82.9% for high-risk group.

5. Median follow-up was 6.1 years.

6. HER2DX provides meaningful stratification beyond clinical variables.

7. Used to tailor treatment intensity and guide clinical decision-making.